Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis

Background: Glioblastoma (GBM) is a highly aggressive cancer with poor prognosis that needs better treatment modalities. Moreover, there is a lack of reliable biomarkers to predict the response and outcome of current or newly designed therapies. While several molecular markers have been proposed as...

Descripción completa

Detalles Bibliográficos
Autores principales: Sareen, Heena, Ma, Yafeng, Becker, Therese M., Roberts, Tara L., de Souza, Paul, Powter, Branka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408540/
https://www.ncbi.nlm.nih.gov/pubmed/36012105
http://dx.doi.org/10.3390/ijms23168835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408540/
https://www.ncbi.nlm.nih.gov/pubmed/36012105
http://dx.doi.org/10.3390/ijms23168835

Ejemplares similares